SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tell A.)
 

Sökning: WFRF:(Tell A.) > Vitamin B6 cataboli...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007380naa a2200985 4500
001oai:lup.lub.lu.se:e9447c24-a56c-4f94-8661-7375d4771ad0
003SwePub
008190502s2019 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-158604
024a https://lup.lub.lu.se/record/e9447c24-a56c-4f94-8661-7375d4771ad02 URI
024a https://doi.org/10.1093/annonc/mdz0022 DOI
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1586042 URI
040 a (SwePub)lud (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Zuo, H.u University of Bergen4 aut
2451 0a Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)
264 1b Elsevier BV,c 2019
300 a 8 s.
520 a Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a inflammation
653 a lung cancer
653 a Lung Cancer Cohort Consortium
653 a nested case-control study
653 a PAr
653 a vitamin B6
653 a PAr
700a Ueland, P. M.u University of Bergen,Haukeland University Hospital,Bevital AS,Fred Hutchinson Cancer Research Center4 aut
700a Tell, G. S.u University of Bergen,University of Paris-Saclay,Human Genetics Foundation (HuGeF)4 aut
700a Fanidi, A.u University of Cambridge,International Agency for Research on Cancer, World Health Organization4 aut
700a Zheng, W.u Vanderbilt University4 aut
700a Shu, X.u Vanderbilt University4 aut
700a Xiang, Y.u Renji Hospital4 aut
700a Wu, J.u Vanderbilt University4 aut0 (Swepub:lu)med-jwu
700a Prentice, R.u Fred Hutchinson Cancer Research Center4 aut
700a Pettinger, M.u Fred Hutchinson Cancer Research Center4 aut
700a Thomson, C. A.u University of Arizona4 aut
700a Giles, G. G.u University of Melbourne,Cancer Council Victoria,National Cancer Institute, USA4 aut
700a Hodge, A.u Cancer Council Victoria,University of Melbourne4 aut
700a Cai, Q.u Vanderbilt University4 aut
700a Blot, W. J.u Vanderbilt University4 aut
700a Johansson, Mikaelu Umeå universitet,Umeå University,Onkologi4 aut0 (Swepub:umu)mijo0025
700a Hultdin, Johanu Umeå universitet,Umeå University,Klinisk kemi4 aut0 (Swepub:umu)johu0007
700a Grankvist, Kjellu Umeå universitet,Umeå University,Klinisk kemi4 aut0 (Swepub:umu)kjgr0002
700a Stevens, V. L.u American Cancer Society4 aut
700a McCullough, M. L.u American Cancer Society4 aut
700a Weinstein, S. J.u National Cancer Institute, USA4 aut
700a Albanes, D.u National Cancer Institute, USA4 aut
700a Ziegler, R. G.u National Cancer Institute, USA4 aut
700a Freedman, N. D.u National Cancer Institute, USA4 aut
700a Caporaso, N. E.u National Cancer Institute, USA4 aut
700a Langhammer, A.u Norwegian University of Science and Technology4 aut
700a Hveem, K.u Norwegian University of Science and Technology4 aut
700a Næss, M.u Norwegian University of Science and Technology4 aut
700a Buring, J. E.u Harvard University,Brigham and Women's Hospital / Harvard Medical School4 aut
700a Lee, I.u Harvard University,Brigham and Women's Hospital / Harvard Medical School4 aut
700a Gaziano, J. M.u Boston Veteran's Administration (VA) Healthcare,Brigham and Women's Hospital / Harvard Medical School,Harvard University4 aut
700a Severi, G.u University of Paris-Saclay,Human Genetics Foundation (HuGeF)4 aut
700a Zhang, X.u Harvard University,Brigham and Women's Hospital / Harvard Medical School4 aut
700a Stampfer, M. J.u Brigham and Women's Hospital / Harvard Medical School,Harvard University4 aut
700a Han, J.u Indiana University4 aut
700a Zeleniuch-Jacquotte, A.u New York University4 aut
700a Marchand, L. L.u University of Hawai'i at Hilo4 aut
700a Yuan, J.u University of Pittsburgh Medical Center4 aut
700a Wang, R.u University of Pittsburgh Medical Center4 aut
700a Koh, W.u National University of Singapore4 aut
700a Gao, Y.u Shanghai Jiao Tong University4 aut
700a Ericson, U.u Lund University,Lunds universitet,Diabetes - kardiovaskulär sjukdom,Forskargrupper vid Lunds universitet,Diabetes - Cardiovascular Disease,Lund University Research Groups4 aut0 (Swepub:lu)medf-upe
700a Visvanathan, K.u Johns Hopkins University School of Medicine4 aut
700a Jones, M. R.u Johns Hopkins University4 aut
700a Relton, C.u University of Bristol,University of Newcastle upon Tyne4 aut
700a Brennan, P.u International Agency for Research on Cancer, World Health Organization4 aut
700a Johansson, M.u International Agency for Research on Cancer, World Health Organization4 aut
700a Ulvik, A.u Bevital AS4 aut
710a University of Bergenb Haukeland University Hospital4 org
773t Annals of Oncologyd : Elsevier BVg 30:3, s. 478-485q 30:3<478-485x 0923-7534x 1569-8041
856u http://dx.doi.org/10.1093/annonc/mdz002y FULLTEXT
856u http://www.annalsofoncology.org/article/S0923753419310828/pdf
8564 8u https://lup.lub.lu.se/record/e9447c24-a56c-4f94-8661-7375d4771ad0
8564 8u https://doi.org/10.1093/annonc/mdz002
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-158604

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy